Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT04704661
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
51 Enrollment(s)
23 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Breast Carcinoma


Advanced Colon Carcinoma


Advanced Colorectal Carcinoma


Advanced Endometrial Carcinoma


Advanced Gastric Carcinoma


Advanced Gastroesophageal Junction Adenocarcinoma


Advanced Malignant Solid Neoplasm


Advanced Salivary Gland Carcinoma


Anatomic Stage III Breast Cancer AJCC v8


Anatomic Stage IV Breast Cancer AJCC v8


Clinical Stage III Gastric Cancer AJCC v8


Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8


Clinical Stage IV Gastric Cancer AJCC v8


Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8


HER2-Positive Breast Carcinoma


Malignant Hepatobiliary Neoplasm


Metastatic Breast Carcinoma


Metastatic Colon Carcinoma


Metastatic Colorectal Carcinoma


Metastatic Endometrial Carcinoma


Metastatic Gastric Carcinoma


Metastatic Gastroesophageal Junction Adenocarcinoma


Metastatic Malignant Solid Neoplasm


Metastatic Salivary Gland Carcinoma


Stage III Colon Cancer AJCC v8


Stage III Colorectal Cancer AJCC v8


Stage III Major Salivary Gland Cancer AJCC v8


Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Stage IV Colon Cancer AJCC v8


Stage IV Colorectal Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8


Unresectable Breast Carcinoma


Unresectable Colon Carcinoma


Unresectable Colorectal Carcinoma


Unresectable Endometrial Carcinoma


Unresectable Gastric Carcinoma


Unresectable Gastroesophageal Junction Adenocarcinoma


Unresectable Malignant Solid Neoplasm


Unresectable Salivary Gland Carcinoma
NOT_YET_RECRUITING
NCT07803393
Mirogabalin Plus EBMP for IC/BPS
200 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Bladder Pain Syndrome


Educational Behavioral Intervention


Urinary Urgency
RECRUITING
NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
600 Enrollment(s)
255 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
RECRUITING
NCT06750484
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
40 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer Metastatic
ACTIVE_NOT_RECRUITING
NCT06271837
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
127 Enrollment(s)
29 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
RECRUITING
NCT05868226
PRE-ISPY Phase I/II Oncology Platform Program
280 Enrollment(s)
10 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
HER2-positive Breast Cancer


Metastatic Cancer


Metastatic Breast Cancer


Metastatic


HER2-positive Metastatic Breast Cancer


HER2 Mutation-Related Tumors


HER-2 Protein Overexpression


HER2-negative Breast Cancer


Triple Negative Breast Cancer


HR Positive


Hormone Receptor-positive Breast Cancer


Estrogen Receptor Positive Tumor


Progesterone Receptor-positive Breast Cancer


Hormone Receptor Negative Breast Carcinoma


Solid Tumor


Solid Tumor, Adult


Solid Carcinoma


HER2 Low Breast Cancer


HER2 Low Breast Carcinoma


ER Positive Breast Cancer


PR-positive Breast Cancer


Minimal Residual Disease


Colo-rectal Cancer


Colon Cancer


Rectal Cancer


ctDNA Monitoring


Colorectal Neoplasms


Colonic Neoplasms


Rectal Neoplasms


Neoplasm, Residual


Adenocarcinoma of Colon


Adenocarcinoma
COMPLETED
NCT03950076
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
948 Enrollment(s)
152 Study location(s)
INTERVENTIONAL (PHASE4)
Intracranial Hemorrhages


Atrial Fibrillation
RECRUITING
NCT02693535
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
4,200 Enrollment(s)
181 Study location(s)
INTERVENTIONAL (PHASE2)
Lymphoma, Non-Hodgkin


Multiple Myeloma


Advanced Solid Tumors